Mark J. Rosenblum, executive VP of finance and CFO, made one open market purchase of Decoy Therapeutics Inc. ($DCOY) shares worth $16,000 in the past year, most recently on November 20, 2025. This ranks 3,996th among nearly 5,000 insiders, well below the average buy of $1.5 million over 3.29 transactions. He reported no open market sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov. 20, 2025 | Decoy Therapeutics Inc. | $DCOY | Rosenblum Mark J | Exec VP Finance, CFO | P | Common Stock | 20000 | $0.80 | 20,177.0000 | 5,862,178 | 9999.99% | 0.34% |
| Feb. 20, 2024 | Decoy Therapeutics Inc. | $DCOY | Rosenblum Mark J | Exec VP Finance, CFO | A | Stock Option (right to buy) | 22500 | $0.00 | 22,500.0000 | 0 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Decoy Therapeutics Inc. | $DCOY | Rosenblum Mark J | Exec VP Finance, CFO | A | Common Stock | 6432 | $0.00 | 21,851.0000 | 0 | 41.71% | 0.00% |
| Jan. 3, 2023 | Decoy Therapeutics Inc. | $DCOY | Rosenblum Mark J | Exec VP Finance, CFO | A | Common Stock | 8000 | $0.00 | 15,419.0000 | 0 | 107.83% | 0.00% |